GLP-1 weight loss plateaus: what the science says vs. TikTok

What did @simidoctors actually say?

The creator laid out three strategies for people stuck on a GLP-1 weight loss plateau: increase your dose, change or start an exercise routine, and add oral supplements that supposedly boost your body's own GLP-1 production while hitting "three other receptors" that help with metabolism and fat burning. They also gave a quick history of FDA-approved GLP-1 medications for weight loss, naming Saxenda, Wegovy, and Zepbound as the approved options.

The supplement pitch was the most pointed part of the video. Rather than naming a specific product, they directed viewers to a link in their bio. That kind of soft-sell structure, health advice plus a monetized link, is worth flagging upfront. It doesn't automatically make the advice wrong, but it does mean you should apply extra scrutiny to the supplement claims specifically.

Does the science back this up?

The dose escalation and exercise advice are both supported by real evidence. The supplement claims are not, at least not with anything close to the confidence implied.

On dose escalation: the STEP trials for semaglutide (Wilding et al., 2021, NEJM) and the SURMOUNT-1 trial for tirzepatide (Jastreboff et al., 2022, NEJM) both showed dose-dependent weight loss, meaning higher doses generally produced more weight loss in people who could tolerate them. Hitting a plateau at a lower dose and then increasing is a medically recognized strategy.

On exercise: a 2023 analysis in Obesity Reviews (Bellicha et al.) found that adding resistance training to GLP-1 therapy helped preserve lean mass during weight loss, which matters for metabolic rate. Simply changing your workout type, say from cardio to resistance training, has biological rationale behind it.

On the oral supplements: the claim that something can "increase your body's own GLP-1 production" plus hit three other metabolic receptors is a very large claim. Some compounds, like berberine, have shown modest GLP-1 stimulating effects in small studies, but the effect sizes are nowhere near what injectable GLP-1 agonists produce. There is no supplement with robust randomized controlled trial evidence matching the efficacy profile implied here.

What did they get wrong (or right)?

The FDA-approved list has a problem. The creator said there are "only three of them in the GLP-1 class that are approved for weight loss," naming Saxenda, Wegovy, and Zepbound. That is mostly accurate as of 2024, but it glosses over important nuance. Tirzepatide (Zepbound) is technically a dual GIP/GLP-1 receptor agonist, not a pure GLP-1 medication. Calling it simply a GLP-1 drug is an oversimplification that matters clinically, since the GIP component is likely part of why tirzepatide outperforms semaglutide in head-to-head weight loss comparisons (Frias et al., 2021, NEJM).

The name errors are minor but sloppy. "Gobi" is presumably Wegovy, and "Manjaro" is Mounjaro. These are phonetic mishaps, but on a platform where people are making health decisions, accuracy in drug names matters.

The supplement claim is the real concern. Saying supplements can hit "three other receptors that help with metabolism" without naming those receptors, citing any evidence, or disclosing a financial relationship with the product is not responsible health communication. The vagueness appears designed to intrigue rather than inform.

What should you actually know?

Weight loss plateaus on GLP-1 therapy are real and well-documented. The body adapts. If you have hit a wall, here is what the evidence actually supports.

• Dose increases are a legitimate clinical tool, but they require physician oversight. Do not self-adjust injectable medications.
• Exercise type matters more than most people realize. Resistance training preserves muscle mass during GLP-1-assisted weight loss, which protects your resting metabolic rate long term.
• No oral supplement currently has clinical trial evidence supporting it as a meaningful GLP-1 booster at the scale these medications work. Berberine, the most studied candidate, shows modest effects in small trials with significant limitations.
• If you are genuinely stuck, a conversation with your prescriber about dose, medication switch, or adjunct behavioral strategies is the appropriate next step, not a supplement from a link in someone's bio.
• The claim that supplements hit "three other receptors" for fat burning is not backed by any named receptor system or cited study in this video. That alone should give you pause.

Bottom line: should you trust this video?

The exercise and dose escalation advice is grounded in legitimate science. Credit where it is due. But the supplement pitch is vague, commercially motivated, and not backed by evidence presented in the video. When a healthcare creator pairs real medical advice with a monetized supplement link and zero citations, the responsible move is to separate the two. Take the exercise advice. Skip the link in bio.